Table 4.
Incidence of mortality and adverse events in MSC-treated and control groups.
| Sources | MSC-treated | Control | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number of death events | Number of patients with AEs | Number of patients with SAEs | Total | Mortality rate (%) | Number of death events | Number of patients with AEs | Number of patients with SAEs | Total | Mortality rate (%) | |
| Adas et al.
21
Turkey |
3 | N/A | N/A | 10 | 30 | 6 | N/A | N/A | 10 | 60 |
| Dilogo et al.
22
Indonesia |
10 | N/A | N/A | 20 | 50 | 16 | N/A | N/A | 20 | 80 |
| Lanzoni et al.
19
United States |
2 | 8 | 2 | 12 | 16.67 | 7 | 11 | 8 | 12 | 58.33 |
| Liang et al.
23
China *Case report |
0 | 0 | 0 | 1 | 0 | N/A | N/A | N/A | N/A | N/A |
| Monsel et al.
20
France |
5 | 18 | 6 | 21 | 23.81 | 4 | 18 | 6 | 24 | 16.67 |
| Rebelatto et al.
24
Brazil |
5 | N/A | N/A | 11 | 45.45 | 1 | N/A | N/A | 6 | 16.67 |
| Shu et al.
25
China |
0 | N/A | N/A | 12 | 0 | 3 | N/A | N/A | 29 | 10.34 |
| Zhu et al.
26
China *Case report |
0 | 0 | 0 | 1 | 0 | N/A | N/A | N/A | N/A | N/A |
AE, adverse event; N/A, not available; MSC, mesenchymal stromal/stem cell; SAE, serious adverse event.